The FDA-cleared Spectral CT 7500 RT, a detector-based computed tomography radiotherapy solution aimed to enhance radiation ...

Joshua K. Sabari, MD, describes the mechanism of action of lurbinectedin as a synthetic alkaloid that binds to guanine ...

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay ...

The 22nd Annual Winter Lung Cancer Conference® will explore advances in neoadjuvant/adjuvant therapies. The FDA has approved Obe-cel for R/R B-ALL, and new treatments in SCLC, lurbinectedin and ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Yanghee Woo, MD, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction ...

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...

The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction ...